Review

Discovery Medicine 2025; 37(197): 976–983
https://doi.org/10.24976/Discov.Med.202537197.87

A Review Article: Evaluation of the Frequency of Genetic Mutations in Leukemia

Abdullah Hamadi[1,*]

[1]Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, 47512 Tabuk, Saudi Arabia
*Correspondence: a.aldhafri@ut.edu.sa (Abdullah Hamadi)
Published: 9 June 2025

Leukemia, a group of malignant blood disorders, arises from the uncontrolled proliferation of abnormal white blood cells. Genetic mutations play a critical role in the initiation and progression of leukemia. This review aims to provide an overview of the genetic landscape of leukemia, focusing on the most common genetic alterations and their clinical implications. A literature search was conducted to identify relevant studies on genetic mutations in leukemia. The identified studies were critically appraised to assess their methodological quality. The present review highlights the key genetic alterations associated with different types of leukemia, including chromosomal translocations, point mutations, and gene copy number variations. These genetic abnormalities can impact disease prognosis, treatment response, and overall patient survival. A comprehensive understanding of the genetic basis of leukemia is essential for accurate diagnosis, prognostication, and the development of targeted therapies. Future research should focus on identifying novel genetic markers, elucidating the underlying mechanisms of leukemogenesis, and developing innovative therapeutic strategies.

Keywords: genetic mutation; leukemia; acute myeloid leukemia; chronic myeloid leukemia; genetics

Introduction

Leukemia, a malignant blood disorder, is characterized by the uncontrolled proliferation of abnormal white blood cells in the bone marrow. This aberrant cellular growth results from a complex interplay of genetic and environmental factors that disrupt the normal hematopoietic process [1]. The etiology of leukemia is multifaceted, with genetic factors playing a central role. Genetic mutations, including chromosomal translocations, point mutations, and gene copy number variations, can lead to the activation of oncogenic signaling pathways and the dysregulation of cell cycle control. These genetic alterations can disrupt normal cellular processes, leading to uncontrolled cell proliferation and the development of leukemia [2].

Traditional treatments for leukemia, such as chemotherapy and radiation therapy, have significantly improved patient outcomes. However, these therapies often have severe side effects and may not be effective in all cases. In recent years, targeted therapies that specifically target the molecular drivers of leukemia have emerged as promising treatment options. These targeted therapies, such as tyrosine kinase inhibitors and immunotherapy, offer more precise and less toxic approaches to treating leukemia [3].

Despite significant advancements in the treatment of leukemia, several challenges remain. One major challenge is the development of drug resistance, as leukemia cells can acquire mutations that confer resistance to targeted therapies. Additionally, the heterogeneity of leukemia and the presence of rare genetic subtypes can complicate treatment decisions.

To address these challenges, a comprehensive understanding of the genetic landscape of leukemia is essential. By identifying the specific genetic alterations that drive the disease, researchers can develop more targeted and effective therapies. This review aims to provide a comprehensive overview of the genetic basis of leukemia, focusing on the most common genetic mutations and their clinical implications.

This review will explore the following key areas:

Definition of Leukemia: A brief overview of the different types of leukemia and their clinical manifestations.

Genetic Alterations in Leukemia: A detailed discussion of the most common genetic mutations associated with leukemia, including chromosomal translocations, point mutations, and gene copy number variations.

The Impact of Genetic Mutations on Leukemia: The role of genetic mutations in the pathogenesis, progression, and prognosis of leukemia.

Targeted Therapies for Leukemia: The development and clinical application of targeted therapies based on genetic alterations.

Future Directions: Emerging trends in leukemia research, including the potential of immunotherapy and gene therapy.

Table 1. Classification of leukemia [1].

Serial number	Classification of leukemia	Description
1	acute lymphoblastic leukemia (ALL)	This type of leukemia primarily affects lymphoid cells, which are a type of white blood cell responsible for producing antibodies. ALL is more common in children than adults and is characterized by the rapid growth of immature lymphoblasts.
2	acute myeloid leukemia (AML)	AML affects myeloid cells, which are responsible for producing red blood cells, platelets, and some white blood cells. It can occur in both children and adults. AML is characterized by the rapid growth of abnormal myeloblasts, which fail to mature into healthy blood cells.
3	chronic lymphocytic leukemia (CLL)	CLL affects lymphocytes, a type of white blood cell responsible for fighting infections. It is more common in adults, especially those over the age of 60. CLL progresses slowly, with the accumulation of abnormal lymphocytes.
4	chronic myeloid leukemia (CML)	CML affects myeloid cells and usually occurs in adults. It is characterized by the excessive production of mature, but abnormal, white blood cells called granulocytes. CML often progresses slowly at first, but can accelerate to a more aggressive phase over time.

By delving into these areas, this review aims to provide valuable insights into the genetic basis of leukemia and to inform future research and clinical practice.

Types and Classification of Leukemia

An abnormally high number of white blood cells is produced in leukemia. Leukemia is a form of malignancy that affects the bone marrow and blood. Depending on the kind of white blood cells involved and the rate at which the disease progresses, it may be roughly divided into four primary categories. Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML) are some of these forms as described in Table 1 (Ref. [1]).

When evaluating the frequency of genetic mutations in leukemia, multiple specific mutations have been identified in different types of leukemia. These mutations play an important role in the development and progression of the disease. Some common genetic mutations associated with leukemia are described in Table 2 (Ref. [2–4]).

Methodology for Evaluating the Frequency of Genetic Mutations

Leukemia genetic mutation frequency assessment requires a comprehensive methodology that integrates a number of laboratory procedures and analytical methods. The methodology's broad overview is described below [5]:

Sample Collection: A sample of leukemia cells is obtained that is representative of the patient population. Depending on the kind of leukemia, this can be accomplished either through bone marrow aspiration or peripheral blood collection.

DNA Extraction: Using standardized laboratory techniques, the genomic DNA is isolated from the leukemia cells. This process makes sure that the genetic material is clean and devoid of impurities.

Mutation Screening: Using mutation screening can screen for certain genetic changes linked to leukemia. Several methods, including the polymerase chain reaction (PCR), DNA sequencing, and fluorescence *in situ* hybridization (FISH), can be used to do this [6,7]. Targeted mutation analysis is a technique that may be used to find particular mutations that have previously been linked to leukemia. These tests are intended to magnify and examine the DNA areas surrounding the identified alterations [8].

By using a qPCR enrichment and quantification stage followed by Sanger or Next-Generation Sequencing (NGS) to validate mutations, selective mutation enrichment provides very sensitive circulating tumor DNA (ctDNA) analysis. Sequencing is done after performing PCR, which increases confidence in the results. The switch-blocker technique produces extremely high sensitivity and specificity by enriching oncogene mutations and suppressing wild-type (WT) DNA. The quantitative nature of all ctDNA testing makes it possible to track the mutation burden. Future panel development and multiplexing are made possible by NGS technology [7].

Comprehensive Mutation Profiling: NGS methods like whole-genome sequencing (WGS) or targeted gene panel sequencing can be used when the mutational landscape is ill-defined [9]. NGS enables the simultaneous investigation of many genes or the entire genome, giving researchers a thorough understanding of the genetic changes that leukemia cells have undergone.

Steps in Comprehensive Mutation Profiling

1. Data analysis: Genetic mutations are looked up using the sequencing data. The sequenced reads are aligned to a reference genome in this stage, and then the variations are called to detect mutations and filtered based on quality and frequency.
2. Validate the detected mutations using further methods, such as digital PCR or Sanger sequencing. This pro-

Table 2. Genetic mutations and their significance in leukemia [2–4].

Types of leukemia	Genetic mutations	Significance
Acute lymphoblastic leukemia (ALL)	Philadelphia chromosome: This mutation involves a reciprocal translocation between chromosomes 9 and 22, resulting in the formation of the breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (*BCR-ABL*) fusion gene. It is primarily found in adults with ALL. Ikaros family zinc finger 1 (*IKZF1*) deletion: Deletion of the *IKZF1* gene is associated with a poor prognosis in ALL patients. ETS variant 6- Runt-related transcription factor 1 (*ETV6-RUNX1*) fusion gene: This fusion gene is commonly found in childhood ALL and is associated with a good prognosis.	Associated with poor prognosis, treatment resistance, and specific therapeutic targets.
Acute myeloid leukemia (AML)	FLT3 stands for Fms-like tyrosine kinase 3 (*FLT3*) mutation: Internal tandem duplications (*ITDs*) or point mutations in the *FLT3* gene are frequently observed in AML and are associated with poor prognosis. Nucleophosmin 1 (*NPM1*) mutation: *NPM1* mutations are the most common genetic alteration in AML and have favorable prognostic implications. CCAAT/enhancer-binding protein alpha (*CEBPA*) mutation: Mutations in the *CEBPA* gene are associated with a better prognosis in AML.	Impact prognosis, response to therapy, and potential for targeted therapies.
Chronic lymphocytic leukemia (CLL)	Tumor protein p53 (*TP53*) mutation: *TP53* mutations are associated with an aggressive form of CLL and a poor prognosis. Neurogenic locus notch homolog protein 1 (*NOTCH1*) mutation: *NOTCH1* mutations are frequently found in CLL and are associated with disease progression. Splicing factor 3b subunit 1 (*SF3B1*) mutation: *SF3B1* mutations are associated with a better prognosis in CLL.	Associated with disease progression, treatment resistance, and patient survival.
Chronic myeloid leukemia (CML)	*BCR-ABL* fusion gene: The *BCR-ABL* fusion gene resulting from the Philadelphia chromosome is the hallmark genetic abnormality in CML. It leads to the production of a constitutively active tyrosine kinase, driving the overgrowth of myeloid cells.	Drives disease progression and is a major target for tyrosine kinase inhibitors.

cess verifies the existence of the mutations and guarantees the reliability of the findings.

3. The frequency of each mutation in the leukemia sample is calculated by quantifying the mutation frequency. This may be done by figuring out the mutant allele frequency, which is the ratio of mutated alleles to alleles overall in a particular genomic site.

4. Later, the data is analyzed on mutation frequency using the proper statistical techniques. This might entail comparing mutation rates of various patient samples or leukemia subtypes, looking for relationships with clinical outcomes, or conducting other pertinent analyses.

5. Reporting and interpretation: The findings in light of are considered what is known currently regarding mutations associated with leukemia. A thorough report outlining the discovered mutations, their prevalence, and any pertinent clinical ramifications is sent [10].

It's crucial to remember that the particular approach may change based on the kind of leukemia, the resources at hand, and the goals of the study or the therapeutic setting. The reliability and repeatability of the results can be further improved by collaboration with subject-matter specialists and adherence to established methods and recommendations.

Table 3. Limitations in evaluating genetic mutations.

Serial number	Limitations	Description	Strategies to enhance accuracy
1	sample size	A small sample size can lead to biased results.	1. Include larger and more diverse patient cohorts. 2. Stratify the sample by relevant factors like age, ethnicity, and leukemia subtype [25].
2	genetic heterogeneity	Individuals and groups have varying genetic mutations.	1. Account for ancestral backgrounds and population stratification. 2. Utilize targeted sequencing panels specific to leukemia subtypes [25,26].
3	detection methodology	Different methods have limitations.	1. Combine multiple detection methods like polymerase chain reaction (PCR), sequencing, and microarrays to overcome individual limitations. 2. Validate findings with orthogonal techniques [27].
4	selection bias	The selection of patients can skew results.	1. Employ case-control studies with matched controls. 2. Include patients with varying disease severities and family histories [27].
5	germline vs. somatic mutations	Distinguishing between mutation types is crucial.	1. Utilize whole-genome sequencing to differentiate germline and somatic mutations. 2. Analyze family history and pedigree information [27].
6	population stratification	Ethnic groups can have varying mutation frequencies.	1. Adjust for population stratification in statistical analyses. 2. Use ancestry informative markers (AIMs) to identify population subgroups.
7	variants of uncertain significance (VUS)	VUS can confound interpretation.	1. Prioritize well-characterized mutations with functional or clinical significance. 2. Utilize functional assays to assess the impact of VUS.
8	dynamic nature of mutations	Mutation frequencies can change over time.	1. Conduct longitudinal studies to track mutation frequencies in leukemia populations. 2. Utilize large-scale databases with historical and contemporary data.

Commonly Identified Genetic Mutations in Leukemia

Several genetic mutations have been identified in different types of leukemia, significantly influencing their development and progression. In acute lymphoblastic leukemia (ALL), the Philadelphia chromosome (breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (*BCR-ABL*) fusion gene), Ikaros family zinc finger 1 (*IKZF1*) deletions, and ETS variant 6- Runt-related transcription factor 1 (*ETV6-RUNX1*) fusions are common genetic alterations. Acute myeloid leukemia (AML) is often associated with mutations in FLT3 stands for Fms-like tyrosine kinase 3 (*FLT3*), Nucleophosmin 1 (*NPM1*), and CCAAT/enhancer-binding protein alpha (*CEBPA*) genes. In chronic lymphocytic leukemia (CLL), tumor protein p53 (*TP53*), Neurogenic locus notch homolog protein 1 (*NOTCH1*), and Splicing factor 3b subunit 1 (*SF3B1*) mutations are frequently observed. Finally, chronic myeloid leukemia (CML) is characterized by the presence of the *BCR-ABL* fusion gene resulting from the Philadelphia chromosome translocation. Understanding these genetic mutations is crucial for accurate diagnosis, risk stratification, and targeted therapy in leukemia patients [8,11,12].

Impact of Genetic Mutations on Leukemia Prognosis and Treatment

Genetic abnormalities are extremely important in determining the prognosis and course of treatment of leukemia.

Prognosis: Genetic changes in leukemia can tell us vital things about how the disease will progress. While certain mutations may be associated with a worse prognosis and more severe types of leukemia, others may be associated with a better prognosis. For instance, compared to other forms of leukemia, chronic myeloid leukemia (CML) has a worse prognosis if it has the Philadelphia chromosome, a genetic anomaly involving the fusion of two genes [13].

The likelihood of a recurrence following therapy can also be affected by genetic abnormalities. For instance, particular genetic changes, such as *MLL* gene rearrangements or the presence of the *BCR-ABL* fusion gene, are linked to an increased risk of recurrence in acute lymphoblastic leukemia (ALL).

Treatment: Leukemia genetic abnormalities can inform treatment choices and assist in tailoring therapy for specific individuals. Utilizing targeted medicines, cancer

Table 4. Future directions and implications.

Serial number	Future directions	Implications
1	personalized medicine	Based on each patient's particular genetic make-up, the features of their condition, and how they respond to treatment, personalized medicine seeks to customize treatment plans for them [24]. The development of targeted medicines has been facilitated by improvements in genome sequencing and analysis, which have revealed insights into the genetic changes underlying leukemia. Future therapies that are more accurate and effective, avoiding side effects, and increasing patient outcomes may be made possible by increased understanding of genetic and molecular markers [28].
2	immunotherapies	Ongoing research aims to improve the efficacy and safety of these therapies, expand their applications to other subtypes of leukemia, and overcome resistance mechanisms. Combination approaches, including the use of immunotherapies with targeted agents or conventional chemotherapy, may further improve treatment [10,14].
3	novel therapeutic targets	One of the main areas of study is finding and focusing on new molecular pathways involved in the development of leukemia. Numerous novel targets are being investigated by researchers, including signaling pathways, epigenetic changes, and particular mutations. By identifying leukemia cells' weaknesses, new medications can be created to specifically disrupt these pathways and enhance therapeutic results [29].
4	gene editing technologies	The development of gene editing tools like Clustered Regularly Interspaced Short Palindromic Repeats – CRISPR-associated protein 9 (CRISPR-Cas9) has created opportunities for precise genetic material change. These technologies may be used to treat leukemia by reversing the genetic defects that lead to the disease's onset or by engineering immune cells to have stronger anti-leukemic properties. However, before gene editing techniques can be applied in clinical settings, significant studies and rigorous safety testing are needed [30].
5	liquid biopsies	Liquid biopsies provide a non-invasive alternative to traditional biopsies for tracking disease progression and therapeutic response. In order to offer real-time information on the genetic make-up of the illness, these tests examine circulating tumor DNA, RNA, and other biomarkers in the blood. Liquid biopsies may aid in early recurrence identification, therapy planning, and monitoring of minimal residual disease [31].
6	supportive care and survivorship	Focusing on supportive care and survivorship becomes more crucial as survival rates rise. Future initiatives should focus on addressing long-term consequences, improving the quality of life for leukemia survivors, and maximizing the management of treatment-related adverse effects. This includes emotional support, therapeutic assistance, and dealing with side effects, including cardiovascular issues or secondary cancers.
7	big data and artificial intelligence	Large datasets are becoming more widely available, and advances in artificial intelligence (AI) provide possibilities for better leukemia management. AI algorithms can help with difficult genetic data analysis, therapy response prediction, and finding new therapeutic targets. Real-time patient data and the integration of electronic health records can also help with clinical decision-making and offer individualized treatment options.

cells with certain genetic abnormalities are frequently targeted while healthy cells are left unaffected [14].

Tyrosine kinase inhibitors (TKIs) are one of the most well-known instances of targeted treatment and are used to treat chronic myeloid leukemia (CML) patients who carry the *BCR-ABL* fusion gene. TKIs that successfully target the aberrant BCR-ABL protein, such as imatinib, nilotinib, and dasatinib, have considerably improved the prognosis for CML patients [15,16].

Similar to this, all-trans retinoic acid (*ATRA*) and arsenic trioxide (*ATO*) can be used in conjunction to treat individuals with acute promyelocytic leukemia (APL) who have the unique genetic mutation known as the promyelocytic leukemia-retinoic acid receptor alpha (*PML-RARA*) fusion gene. The survival rates for APL patients have been significantly increased by this focused treatment [17,18].

Genetic testing can assist in identifying individuals who could benefit from hematopoietic stem cell transplantation (HSCT) in addition to targeted therapy. In certain in-

stances, HSCT, which includes replacing the patient's damaged bone marrow with healthy stem cells, proves curative. Genetic mutations can help in the decision-making process by identifying individuals who are more likely to experience a relapse or who are more likely to respond favorably to HSCT [19].

Genetic Testing and Its Role in Detecting Mutations in Leukemia

Leukemia is prone to genetic abnormalities, which can provide crucial details about the disease subtype, prognosis, and available treatments. Here are some examples of how genetic testing is applied to leukemia [20]:

Chromosomal Analysis: Chromosomal analysis is a method used to detect particular chromosomal abnormalities in leukemia cells, including translocations or deletions. The Philadelphia chromosome, which is linked to CML, is one example [21].

FISH: FISH is a genetic diagnostic procedure that is used to find gene rearrangements or deletions linked to various subtypes of leukemia. It is especially helpful in finding abnormalities that are difficult to find using other techniques [6].

PCR: PCR is used to identify genetic changes linked to certain leukemia subtypes, such as the CML-associated *BCR-ABL* fusion gene [22].

NGS: The sequencing of several DNA or RNA molecules at once is made possible by NGS technologies, which revolutionize genetic testing by enabling the examination of multiple genes or whole genomes in a single test [23].

Hematologists and oncologists can more precisely categorize leukemia subtypes, customize treatment plans, and forecast patient outcomes thanks to genetic testing. It is often carried out on blood or bone marrow samples collected by techniques like peripheral blood drawing or bone marrow aspiration [24]. Depending on the healthcare institution, the available technology, and the patient's circumstances, several testing procedures may be employed. In order to offer a thorough picture of the condition, genetic testing is frequently conducted in combination with other diagnostic procedures.

Challenges and Limitations in Evaluating the Frequency of Genetic Mutations

Due to several variables at play, determining the frequency of genetic changes is fraught with difficulties and has its limitations. The following are some of the primary difficulties and restrictions in Table 3 (Ref. [25–27]):

Future Directions and Implications for Leukemia Management

The therapy and management of leukemia have advanced significantly over time, and current research continues to investigate novel avenues and implications for these challenging conditions. Here are some possible directions for the future and their implications in Table 4 (Ref. [10,14,24,28–31]):

Novel Mutations or Emerging Research in the Field of Leukemia Genetics

While this review primarily focuses on well-established genetic mutations in leukemia, it's important to acknowledge the rapidly evolving landscape of leukemia research. Recent studies have identified novel mutations, such as those in the isocitrate dehydrogenase (NADP(+)) 1, cytosolic (*IDH1*) and isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (*IDH2*) genes, which have significant implications for diagnosis and targeted therapy. Additionally, emerging research on epigenetic modifications and microRNA dysregulation is shedding new light on the complex mechanisms underlying leukemia development. By incorporating these emerging findings into future studies, researchers can further refine our understanding of leukemia genetics and develop more effective treatment strategies. It is crucial to keep in mind that while these new avenues have a lot of potential, they will also need a lot of study, thorough clinical testing, regulatory clearances, and consideration of the ethical and societal consequences. Nevertheless, in the upcoming years, these developments might fundamentally alter the area of leukemia care and enhance patient outcomes.

Conclusion

Genetic mutations play a critical role in the development and progression of leukemia. By understanding the specific genetic alterations associated with different leukemia subtypes, we can improve diagnosis, risk stratification, and treatment decisions. However, the complex genetic landscape of leukemia necessitates further research to fully elucidate the underlying mechanisms and identify novel therapeutic targets. Future research should focus on: Comprehensive Genomic Profiling: To identify novel genetic alterations and refine our understanding of the complex genetic landscape of leukemia.

Functional Studies: To elucidate the mechanisms underlying the impact of specific mutations on leukemia pathogenesis and drug resistance. Population-Based Studies: To investigate the frequency and clinical significance of genetic mutations in diverse populations.

Liquid Biopsy: To enable real-time monitoring of disease progression and treatment response. Personalized medicine: To integrate genetic information into clinical decision-making for more personalized and effective treatment approaches.

By addressing these research areas, we can further advance our understanding of leukemia genetics and improve patient outcomes.

Availability of Data and Materials

Not applicable.

Author Contributions

AA is responsible for conceptualizing the study, conducting the literature review, analyzing and interpreting the data, and drafting the initial manuscript. AA has read and approved the final manuscript, participated sufficiently in the work, and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

Not applicable.

Funding

This research received no external funding.

Conflict of Interest

The author declares no conflict of interest.

References

[1] Chennamadhavuni A, Lyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023. Available at: http://www.ncbi.nlm.nih.gov/books/NBK560490/ (Accessed: 16 May 2023).

[2] Wang S, Wu Z, Li T, Li Y, Wang W, Hao Q, *et al*. Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia. Scientific Reports. 2020; 10: 12152.

[3] Petti AA, Williams SR, Miller CA, Fiddes IT, Srivatsan SN, Chen DY, *et al*. A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing. Nature Communications. 2019; 10: 3660.

[4] Pettirossi V, Venanzi A, Spanhol-Rosseto A, Schiavoni G, Santi A, Tasselli L, *et al*. The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor. Leukemia. 2023; 37: 473–477.

[5] Rannala B, Qiu WG, Dykhuizen DE. Methods for estimating gene frequencies and detecting selection in bacterial populations. Genetics. 2000; 155: 499–508.

[6] Alliance G, Screening Services TNYMAC for G and N. GENETIC TESTING METHODOLOGIES. In: Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. Genetic Alliance. 2009. Available at: https://www.ncbi.nlm.nih.gov/books/NBK115548/ (Accessed: 16 May 2023).

[7] Poole JC, Wu SF, Lu TT, Vibat CRT, Pham A, Samuelsz E, *et al*. Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations. PloS One. 2019; 14: e0223112.

[8] Chang YH, Yu CH, Jou ST, Lin CY, Lin KH, Lu MY, *et al*. Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia. Scientific Reports. 2021; 11: 769.

[9] Comprehensive-genomic-profiling. 2021. Available at: https://cup-syndrome.com/en/home/comprehensive-genomic-profiling.html (Accessed: 16 May 2023).

[10] Bielas JH, Loeb LA. Quantification of random genomic mutations. Nature Methods. 2005; 2: 285–290.

[11] Hou HA, Tien HF. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. Journal of Biomedical Science. 2020; 27: 81.

[12] Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, *et al*. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014; 28: 1586–1595.

[13] Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, *et al*. Genomic Classification and Prognosis in Acute Myeloid Leukemia. The New England Journal of Medicine. 2016; 374: 2209–2221.

[14] Malyukova A, Ujvari D, Yektaei-Karin E, Zovko A, Madapura HS, Keszei M, *et al*. A combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells. Cell Death & Disease. 2021; 12: 875.

[15] Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nature Reviews. Clinical Oncology. 2017; 14: 141–154.

[16] Gild ML, Tsang VHM, Clifton-Bligh RJ, Robinson BG. Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nature Reviews. Endocrinology. 2021; 17: 225–234.

[17] Wang HY, Gong S, Li GH, Yao YZ, Zheng YS, Lu XH, *et al*. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Blood Cancer Journal. 2022; 12: 158.

[18] Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, *et al*. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. The New England Journal of Medicine. 2013; 369: 111–121.

[19] Kallianpur AR. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come? Bone Marrow Transplantation. 2005; 35: 1–16.

[20] Montazerinezhad S, Emamjomeh A, Hajieghrari B. Chromosomal abnormality, laboratory techniques, tools and databases in molecular Cytogenetics. Molecular Biology Reports. 2020; 47: 9055–9073.

[21] Chromosome Analysis - an overview | ScienceDirect Topics. 2015. Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/chromosome-analysis (Accessed: 16 May 2023).

[22] Ozkan E, Lacerda MP. Genetics, Cytogenetic Testing and Conventional Karyotype. StatPearls Publishing: Treasure Island. 2023. Available at: http://www.ncbi.nlm.nih.gov/books/NBK563293/ (Accessed: 16 May 2023).

[23] Behjati S, Tarpey PS. What is next generation sequencing? Archives of Disease in Childhood. Education and Practice Edition. 2013; 98: 236–238.

[24] Schlegelberger B, Mecucci C, Wlodarski M. Review of guidelines for the identification and clinical care of patients with genetic predisposition for hematological malignancies. Familial Cancer. 2021; 20: 295–303.

[25] Feng G, Jensen FE, Greely HT, Okano H, Treue S, Roberts AC, *et al*. Opportunities and limitations of genetically modified nonhuman primate models for neuroscience research. Proceedings of the National Academy of Sciences of the United States of America. 2020; 117: 24022–24031.

[26] Kaya C, Dorsaint P, Mercurio S, Campbell AM, Eng KW, Niki-

forova MN, *et al*. Limitations of Detecting Genetic Variants from the RNA Sequencing Data in Tissue and Fine-Needle Aspiration Samples. Thyroid: Official Journal of the American Thyroid Association. 2021; 31: 589–595.

[27] Liang D, Mikhalchenko A, Ma H, Marti Gutierrez N, Chen T, Lee Y, *et al*. Limitations of gene editing assessments in human preimplantation embryos. Nature Communications. 2023; 14: 1219.

[28] Davis AS, Viera AJ, Mead MD. Leukemia: an overview for primary care. American Family Physician. 2014; 89: 731–738.

[29] Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. British Journal of Haematology. 2022; 196: 316–328.

[30] Rohman M. Exploring Novel Mechanisms and Therapeutic Targets for Acute Myeloid Leukemia. News Center. 2022. Available at: https://news.feinberg.northwestern.edu/2022/10/26/exploring-novel-mechanisms-and-therapeutic-targets-for-acute-myeloid-leukemia/ (Accessed: 16 May 2023).

[31] Mithraprabhu S, Chen M, Savvidou I, Reale A, Spencer A. Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders. Leukemia. 2021; 35: 2771–2783.